NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Short Interest Up 29.2% in October

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 51,800 shares, an increase of 29.2% from the September 30th total of 40,100 shares. Based on an average trading volume of 69,400 shares, the short-interest ratio is presently 0.7 days. Currently, 2.9% of the shares of the company are short sold.

Institutional Investors Weigh In On NLS Pharmaceutics

A hedge fund recently raised its stake in NLS Pharmaceutics stock. Armistice Capital LLC raised its holdings in shares of NLS Pharmaceutics Ltd. (NASDAQ:NLSP) by 6.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,311,000 shares of the company’s stock after acquiring an additional 139,000 shares during the quarter. Armistice Capital LLC owned approximately 19.62% of NLS Pharmaceutics worth $501,000 as of its most recent SEC filing.

NLS Pharmaceutics Stock Performance

NLSP traded up $0.02 during midday trading on Tuesday, reaching $4.13. The company had a trading volume of 19,133 shares, compared to its average volume of 101,726. NLS Pharmaceutics has a 1 year low of $3.80 and a 1 year high of $29.69. The business has a 50-day moving average of $2.20 and a two-hundred day moving average of $0.88.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).